05483nam 22014293a 450 991036775470332120250203235431.09783039211906303921190010.3390/books978-3-03921-190-6(CKB)4100000010106170(oapen)https://directory.doabooks.org/handle/20.500.12854/61900(ScCtBLL)7f92ff81-7eac-47f9-98c7-07aa248d0431(OCoLC)1163853203(oapen)doab61900(EXLCZ)99410000001010617020250203i20192019 uu engurmn|---annantxtrdacontentcrdamediacrrdacarrierVenom and Toxin as Targeted TherapyHang Fai Henry KwokMDPI - Multidisciplinary Digital Publishing Institute2019Basel, Switzerland :MDPI,2019.1 electronic resource (180 p.)9783039211890 3039211897 Targeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers.Biology, life sciencesbicssccane toadB cell non-Hodgkin lymphomaMalaysian cobrascomplement systemdecay accelerating factorneuroblastomaatopic dermatitiscomplement dependent cytotoxicityantioxidant enzymesbacterial adhesioncancer therapyN. kaouthiaanuran skin secretionfrogApis mellifera syriacasolid phase extractionbee venom phospholipase A2 (bvPLA2)disintegrintoad toxinsimmunotoxinsribosome-inactivating proteinsantimicrobial peptide (AMP)drug designMoxetumomab pasudotoxsnake venomantiviral activityin vitro effectsbombesin-related peptideoxidative stress biomarkershalf-lifeblood vessel formationtarget therapy2MYCNindolealkylaminesHuachansumembrane attack complexbouganinbee venomSEManticancer activityantimicrobial peptidehouse dust mite extract (DFE)mannose receptorO. hannahbicarinalingastric cellsmelittinLC-ESI-MSdermaseptinsmooth muscleapoptosisanticancerN. sumatranaHelicobacter pyloriinflammationimmunotherapyatopic dermatitis (AD)immunotoxinmantle cell lymphomaclearancemass spectrometryBougainvillearRNA N-glycosylase activityfungal toxinskin inflammationtargeted therapy4-dinitrochlorobenzene (DNCB)Bee venomVEGFChansubufadienolidesobsessive-compulsive disorder (OCD)BLF1antimicrobial activityorellanineVB6-845acute lymphoblastic leukemiaribosome-inactivating proteinCD206molecular cloningcancerCD22eIF4ABiology, life sciencesKwok Hang Fai Henry1320455ScCtBLLScCtBLLBOOK9910367754703321Venom and Toxin as Targeted Therapy3034329UNINA